Middle East conflict drives demand surge in passive cooling packaging as 20% of global air cargo faces disruption

MIDDLE EAST – The Middle East conflict has disrupted more than 20 percent of global air cargo capacity, forcing pharmaceutical companies to rely heavily on passive cooling packaging, insulated boxes, gel packs, and dry ice, as rerouted shipments face extended transit times that push standard thermal packaging to its limits.

Industry data cited by Antwerp Management School reveals that over one-fifth of global air cargo, the primary artery for temperature-sensitive medicines, is exposed to disruption.

The closure of major cargo hubs including Dubai, Abu Dhabi, and Doha has severed established cold chain corridors, redirecting shipments through Saudi Arabia, Oman, and Turkey.

For packaging suppliers, this represents a fundamental shift: cold chain resilience is now driven by packaging performance rather than route predictability.

By the Numbers: The Packaging Market Opportunity

The Middle East and Africa active, smart, and intelligent packaging market reached US$7.23 billion in 2025 and is forecast to grow to US$11.10 billion by 2033 at 5.50 percent CAGR.

Saudi Arabia’s cold chain logistics market is valued at US$2.26 billion in 2026, while the UAE market stands at US$1.72 billion.

As transit times extend, demand for high-performance passive cooling systems is accelerating.

Extended Transit Times Drive Packaging Innovation

Pharmaceutical executives report that Europe-to-Asia cargo typically transiting Dubai is being redirected through Singapore, adding days to delivery windows.

Each additional day in transit can consume 5 to 10 percent more dry ice, forcing packaging engineers to redesign thermal protection systems for longer duration.

Dorothee Becher of Kuehne+Nagel confirmed carriers are reaching Gulf markets through alternative routes, requiring packaging validated for multimodal handling and extended temperature excursions.

Passive systems now account for approximately 60 percent of pharmaceutical cold chain packaging globally, with that share expected to rise as carriers prioritize belly cargo space over dedicated cool dollies.

Packaging Components at Risk

David Weeks of Moody’s noted that shortages may arise for vial stoppers and IV bag plastics, components shipped through the same affected routes.

“It’s not always a shortage of the medicine itself,” Weeks said. “In some cases, it’s the little stopper on the vial where the dosage is extracted” a packaging component critical to drug delivery.

High-Risk Products Demand Superior Packaging

Prashant Yadav of the Council on Foreign Relations identified cancer drugs, particularly monoclonal antibodies, as among the highest-risk products.

These biologics require strict temperature control between 2°C and 8°C, with deviations potentially causing protein degradation.

Typical packaging validation assumes 48-72 hour transit; rerouted shipments now face durations exceeding validated limits.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE